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Objectives: To describe a 10-year single center experience with parotid gland malig-
nancies and to determine factors affecting outcomes.
Study Design: Retrospective review.
Methods: The institutional cancer registry was used to identify patients treated surgi-
cally for malignancies of the parotid gland between January 2005 and December
2014. Clinical and pathologic data were collected retrospectively from patient charts
and analyzed for their association with overall survival (OS) and disease-free sur-
vival (DFS).
Results: Two hundred patients were identified. Mean age at surgery was 57.8 years,
and mean follow-up time was 52 months. One hundred two patients underwent total
parotidectomy, while 77 underwent superficial parotidectomy, and 21 underwent
deep lobe resection. Seventy patients (35%) required facial nerve (FN) sacrifice. Acinic
cell carcinoma was the most common histologic type (22%), followed by
mucoepidermoid carcinoma (21.5%) and adenoid cystic carcinoma (12.5%). Twenty-
nine patients (14.5%) experienced recurrences, with mean time to recurrence of
23.6 months (range: 1-82 months). Five- and 10-year OS were 81% and 73%, respec-
tively. Five- and 10-year DFS were 80% and 73%, respectively. In univariate analyses,
age > 60, histologic type, positive margins, high grade, T-stage, node positivity,
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perineural invasion, and FN involvement were predictors of OS and DFS. In the multi-
variate analysis, histology, positive margins, node positivity, and FN involvement were
independent predictors of OS and DFS.
Conclusions: Our single-center experience of 200 patients suggests that histology,
positive margins, node positivity, and FN involvement are independently associated
with outcomes in parotid malignancies.
Level of Evidence: 4
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1 | INTRODUCTION
Neoplasms of the salivary glands comprise a diverse group of at least
20 histologically distinct disease entities and frequently pose diagnostic
and management challenges.1 This may be further complicated by histo-
logic diversity within the same surgical specimen and co-occurrence with
benign entities (eg, carcinoma ex pleomorphic adenoma).2 Together, sali-
vary gland neoplasms account for approximately 6% of all head and neck
neoplasms,3 with an annual incidence of 0.5 to 2.0 per 100 000 in the
general population.4 Approximately 80% of these tumors involve the
parotid gland. An estimated 20% to 25% are malignant in nature, with
mucoepidermoid carcinoma described as the most common histology.
There are differences in incidence between males and females, with
mucoepidermoid carcinomas more common in males and acinic cell and
adenoid cystic carcinomas found more commonly among females.5
Surgical resection is the primary treatment for salivary malig-
nancy. Prognosis varies widely by histologic subtype, with survival
ranging from 95% to 100% for polymorphous low-grade adenocarci-
noma6 to 23% to 50% in cases of high-grade mucoepidermoid carci-
noma.7,8 A variety of factors have been evaluated for prognostic
significance, including histological subtype, tumor grade and stage,
cervical lymphadenopathy, facial nerve (FN) involvement, perineural
invasion (PNI), and positive surgical margins.9-12 Molecular markers
have also been discovered that are associated with prognosis and
survival,13,14 but none are widely used in clinical practice. In addition,
detailed single institution reviews of parotid malignancies over a sub-
stantial time period remain limited. We therefore sought to utilize our
own experience to provide insight into demographics and clinical fea-
tures of parotid gland malignancies over a 10-year period, and thereby
determine clinical and pathologic factors affecting survival and
recurrence.
2 | MATERIALS AND METHODS
This study was reviewed by the Massachusetts Eye and Ear Infirmary
(MEEI) institutional review board and deemed to be of minimal risk.
The institutional cancer registry was used to identify all patients who
underwent surgery for primary malignancy of the parotid gland at
MEEI, a tertiary referral center in Boston, Massachusetts, between
January 2005 and December 2014. Patient charts were reviewed, and
relevant demographic, clinical, and pathologic data were recorded.
Overall survival (OS) was defined as the time elapsed between
the date of surgery and the date of last documented communication
with the patient. Disease-free survival (DFS) was calculated as the
time elapsed between the date of surgery and the date of last docu-
mented note from an oncologic provider (surgeon, medical oncologist,
or radiation oncologist). For patients who had a documented recur-
rence, DFS was calculated as the time elapsed between the date of
surgery and the date of documented recurrence.
For survival analyses, all patients were assumed to be censored
unless documented as deceased (for analyses of OS) or having a recur-
rence (for analyses of DFS). For Cox proportional hazards models, all
predictor variables were simplified to binary values as follows: age
classified as >60 or ≤60, T-stage classified as low (T1 or T2) or high
(T3 or T4), N-stage classified as negative (N0) or positive (N1, N2, or
N3), overall stage classified as early (stage I or II) or advanced (stage III
or IV), grade classified as low (grade 1) or high (grade 2 or 3), and mar-
gin status classified as negative or positive (microscopically or grossly
positive). JMP-Pro version 13 (SAS) was used to generate Kaplan-
Meier survival curves and for univariate and multivariate Cox propor-
tional hazards models.
3 | RESULTS
Two hundred patients (104 men, 96 women, with average age of
57.8 years [range: 10-96 years]) were treated surgically for primary
malignancies of the parotid gland at MEEI between January 2005 and
December 2014. The most common histologies were acinic cell carci-
noma (N = 44), mucoepidermoid carcinoma (N = 43), adenoid cystic
carcinoma (N = 25), salivary duct carcinoma (N = 18), and carcinoma
ex pleomorphic adenoma (N = 15). See Table 1 for a summary of his-
tologic subtypes. For Kaplan-Meier curves and Cox proportional haz-
ards models, all histologic types other than these top five were
grouped under the category “Other Histologies.”
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3.1 | Treatment regimens
Of 200 patients, 77 (33.5%) underwent superficial parotidectomy,
21 (10.5%) underwent deep lobe resection, 14 (7%) underwent subto-
tal parotidectomy, and 88 (44%) underwent total parotidectomy.
Seventy patients (35%) underwent sacrifice of one or more branches
of the FN. Seventy-four patients (37%) underwent cervical
lymphadenectomy. Seventy-seven patients (38.5%) underwent sur-
gery alone, while the remainder received adjuvant therapy, with
81 (41%) receiving adjuvant radiation therapy (XRT) alone, 2 (1%)
receiving adjuvant chemotherapy alone, and 39 (19.5%) receiving
adjuvant chemotherapy and XRT.
3.2 | Pathologic characteristics
Patient charts were retrospectively reviewed for data regarding
AJCC tumor-node-metastasis (TNM) staging, margin status, grade, FN
involvement, PNI, lymphovascular invasion (LVI), and extracapsular
extension (ECE). Patients were distributed across all T stages, includ-
ing Tis (n = 6, 3%), T1 (n = 66, 33%), T2 (n = 51, 25.5%), T3 (n = 31,
15.5%), and T4 (n = 46, 23%). One hundred fifty-seven patients
(78.5%) were N0, with 31 being pN0 and 126 being cN0. The remain-
der were N1 (n = 15, 7.5%), N2 (n = 27, 13.5%), and N3 (n = 1, 0.5%).
Histologic grade was determined at the time of original pathologic
diagnosis and was classified as low grade (grade 1) or high grade
(grade 2 or 3). Grade 2 tumors were classified as high grade to keep
approximately equal numbers of high and low grade tumors. Grade
reporting was incomplete, with 82 patients (41%) having no grade
reported. All 18 cases of salivary duct carcinoma were high grade, and
of the remaining cases, 55 (27.5% of total) were high grade, while
45 (22.5% of total) were low grade. FN involvement was seen in
44 patients (22%), PNI in 51 (25.5%), LVI in 26 (13%), and ECE in
5 (2.5% overall, 10% of node-positive). Sixty-eight patients (34%) had
microscopic or grossly positive margins, while 132 (66%) had negative
margins. Associations between histologic type and clinicopathologic
features are shown in Table 2.
3.3 | Follow-up and recurrence
Mean follow-up time was 4.1 years, and 36 patients (18%) were docu-
mented as deceased over the follow-up period. There were 29 docu-
mented recurrences (14.5% of cases), with a mean time to recurrence
of 23.6 months. Distant recurrence (18/29 cases, 62%) was more
common than local (11/29 cases, 38%) or regional (1/29 cases, 3%)
recurrence, with the most common sites for metastasis being the lung
(14/18 cases), brain, bone, mediastinum, liver, and peritoneum. Cases
of local recurrence were found in the parotid bed (5/11 cases), tempo-
ral bone, external auditory canal, and infratemporal fossa. One patient
experienced both local and regional recurrence, while one patient
experienced both local recurrence and distant metastasis. Four of
11 patients with local recurrence underwent salvage surgery.
3.4 | Survival analysis
Total OS (Figure 1A) was 87%, 81%, and 73%, while total DFS
(Figure 1B) was 84%, 80%, and 73% at 2 years, 5 years, and 10 years,
respectively. There was a significant impact of histology on OS and
DFS, with salivary duct carcinoma and other histologies having the
poorest OS and DFS at 2 and 5 years and adenoid cystic carcinoma,
with a significant number of late recurrences and late deaths, having
the poorest OS and DFS at 10 years (P = .0016 and .0012 for OS and
DFS, respectively). Accordingly, adenoid cystic carcinoma had a signif-
icantly higher average time to recurrence than all other histologic
types (3.92 vs 1.29 years, P = .0017).
3.5 | Predictors of survival
In the univariate Cox proportional hazards model (n = 200 unless oth-
erwise specified), predictors of OS and DFS included age > 60 (hazard
ratio, HR [OS] = 4.1, P = .0001; HR [DFS] = 3.5, P < .0001), “other”
TABLE 1 Summary of histologic types
Histology N %
Acinic cell carcinoma 44 22
Mucoepidermoid carcinoma 43 21.5
Adenoid cystic carcinoma 25 12.5
Salivary duct carcinoma 18 9
Carcinoma ex pleomorphic adenoma 15 7.5
Squamous cell carcinoma 14 7
Adenocarcinoma NOS 5 2.5
Cystadenocarcinoma 5 2.5
Epithelial-myoepithelial carcinoma 4 2
Basal cell adenocarcinoma 3 1.5
Lymphoepithelial carcinoma 3 1.5
Mammary analog secretory carcinoma 3 1.5
Neuroendocrine carcinoma 3 1.5
Basaloid carcinoma 2 1
Carcinoma NOS 2 1
Merkel cell carcinoma 2 1
Myoepithelial carcinoma 2 1
Adenocarcinoma, ductal type 1 0.5
Adenosquamous carcinoma 1 0.5
Clear cell carcinoma 1 0.5
Myofibroblastic sarcoma 1 0.5
Rhabdomyosarcoma 1 0.5
Sebaceous adenocarcinoma 1 0.5
Spindle cell carcinoma 1 0.5
Total 200 100
Abbreviation: NOS, not otherwise specified.
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histology (HR [OS] = 3.2, P = .0008; HR [DFS] = 3.0, P = .0004), posi-
tive margins (HR [OS] = 3.0, P = .001; HR [DFS] = 3.3, P < .0001), high
grade (n = 118; HR [OS] > 100, P < .0001; HR [DFS] > 100,
P < .0001*), advanced T-stage (HR [OS] = 4.5, P < .0001; HR
[DFS] = 5.2, P < .0001), node positivity (HR [OS] = 3.8, P = .0002, HR
[DFS] = 4.0, P < .0001), PNI (HR [OS] = 3.8, P < .0001; HR [DFS] = 3.8,
P < .0001), and FN involvement (HR [OS] = 4.7, P < .0001; HR
[DFS] = 4.8, P < .0001). ECE (n = 50, HR [OS] = 2.9, P = .21; HR
[DFS] = 4.3, P < .05) was associated with DFS but not OS, and LVI
(HR [OS] = 1.6, P = .42; HR [DFS] = 2.1, P = .06) was not associated
with either outcome measure.
All predictors that showed significance in the univariate model were
tested in the multivariate model, except for grade which was incom-
pletely reported and PNI, which was redundant with FN involvement. In
the multivariate model, histology “other,” positive margins, node positiv-
ity, and FN involvement were found to be significant predictors of OS
and DFS, and age > 60 showed a trend in this direction (Table 3).
Kaplan-Meier survival curves for OS and DFS stratified by margin sta-
tus, node positivity, and FN involvement are shown in Figure 2.
4 | DISCUSSION
Here, we report on 200 consecutive cases of parotid malignancies at
our institution over a 10-year period. We found that histologic sub-
type, positive margins, node positivity, and FN involvement were all
independent predictors of poor prognosis.
Our total OS and DFS are consistent with prior reports in the lit-
erature of good prognosis with surgically treated disease.6,12,15-20 In a
report on 2062 patients with parotid carcinomas from the Swedish
cancer registry, the 10 year survival was 71.6% and the figure did not
change significantly from 1960 to 1995.12 Consistent with prior stud-
ies, we found a significant impact of histologic subtype on OS and
DFS. At 2 and 5 years, salivary ductal carcinoma had the poorest OS
of 77% and 68%, respectively, consistent with prior reports of poor
survival in patients with this malignancy but higher than previously
quoted rates of only 20% to 35%.21 At 10 years, adenoid cystic carci-
noma had the poorest OS at 53%, consistent with a propensity for late
recurrence, PNI, and distant metastasis. Prior reports of 5-year sur-
vival ranged from 35% to 70%.22,23 Acinic cell and mucoepidermoid
carcinomas had the best OS at 2, 5, and 10 years. It is notable that in
our study, survival was defined by last known communication, which
may underestimate potential survival since loss to follow-up or trans-
fer of care to alternate providers with incomplete communication is
common in a tertiary referral center.
In our cohort, the recurrence rate was 14.5% and the mean time
to recurrence was 2 years, consistent with reported recurrence rates
of 18.4% to 24.1%.15,17,18 In our cohort, distant metastasis, which was
most common in salivary ductal carcinoma (6/18 cases, 33%), was
more common than locoregional recurrence, consistent with prior
studies.15,18 Salivary ductal carcinomas had the highest rates of early
recurrence, while adenoid cystic carcinoma had the longest time to
recurrence (3.29 years) and the greatest rate for recurrence by
10 years, with an overall recurrence rate of 24%. This propensity for
TABLE 2 Breakdown of histopathologic characteristics by tumor histology
Acinic cell Mucoepidermoid Adenoid cystic Salivary duct Carcinoma ex pleo Other histology P value (chi-square)
PNI
No 42 (95) 39 (91) 12 (48) 5 (28) 13 (87) 38 (69) <.0001
Yes 2 (5) 4 (9) 13 (52) 13 (72) 2 (13) 17 (31)
N stage
N0 40 (91) 38 (88) 22 (88) 6 (33) 12 (80) 39 (71) <.0001
N+ 4 (9) 5 (12) 3 (12) 12 (67) 3 (20) 16 (29)
Grade
Low 3 (43) 28 (65) 10 (59) 0 (0) 0 (0) 3 (10) <.0001
High 4 (57) 15 (35) 7 (41) 18 (100) 2 (100) 28 (90)
Margin
Neg 34 (77) 33 (77) 6 (24) 10 (56) 12 (80) 37 (67) .0001
Pos 10 (23) 10 (23) 19 (76) 8 (44) 3 (20) 18 (33)
LVI
No 42 (96) 42 (98) 25 (100) 10 (56) 12 (80) 43 (78) <.0001
Yes 2 (4) 1 (2) 0 (0) 8 (44) 3 (20) 12 (22)
Stage
Early 36 (82) 30 (70) 12 (48) 3 (17) 9 (60) 17 (31) <.0001
Adv 8 (18) 13 (30) 13 (52) 15 (83) 6 (40) 38 (69)
Total N 44 43 25 18 15 55
Note: There were significant associations of tumor histology with all histopathologic characteristics. Percentages are shown in parentheses.
Abbreviations: Adv, advanced; LVI, lymphovascular invasion; Neg, negative; Pleo, pleomorphic; PNI, perineural invasion; Pos, positive.
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recurrence at 10 years with good DFS at 2 and 5 years underscores
the importance of continued surveillance of patients with adenoid
cystic carcinoma well beyond the 5-year time point, which is gener-
ally considered to be curative for other malignancies. Biologically,
this late recurrence has been attributed to an initial period of relative
growth quiescence, followed by aggressive transformation
manifested by sudden rapid growth, local invasiveness, and distant
metastatic spread.23 To our knowledge, the molecular correlates of
such an aggressive transformation have not been demonstrated and
warrant further investigation in an effort to guide therapies targeting
these lesions.
Several factors were noted to impact survival rates. OS and DFS
were significantly impacted by FN involvement (Figure 2E,F) and N-
stage (Figure 2C,D), and age > 60 showed a trend (Table 3). Many
other studies have similarly demonstrated that older age at presenta-
tion is associated with worse survival outcomes,15,17 perhaps
reflecting the more aggressive nature of late-presenting disease, as
well as the fact that older individuals are likely to have more com-
orbidities, poorer functional status, or weakened immunity.6,17,19 FN
involvement, which was seen in 44 patients (22%) in our cohort, has
previously been demonstrated to be independently associated with
survival outcomes,17,19 though it remains unclear whether this repre-
sents a manifestation of more locally aggressive tumors with skip
lesions that are difficult to completely resect or a propensity for dis-
tant metastasis, as is seen in adenoid cystic carcinoma, which is most
classically associated with perineural spread.
Nodal involvement was associated with significant reduction in
survival. Consistent with prior studies,17,19 5-year OS and DFS, which
were 56% and 46%, respectively, in node-positive patients and 88%
and 83%, respectively, in node-negative patients (Figure 2C,D). The
overall rate of node positivity was 21.5%, which is similar to previous
reports of 18% to 28%.16,17,24 However, in our cohort, this was signif-
icantly associated with intrinsic factors related to the disease entity,
as less than 20% of acinic cell, mucoepidermoid, and adenoid cystic
carcinomas demonstrated node positivity, while 66% of salivary ductal
carcinomas had nodal metastasis at the time of presentation. These
findings suggest that patients with salivary ductal carcinomas should
uniformly receive cervical lymphadenectomy at the time of primary
tumor removal, while those with other histologic types may be consid-
ered on an individualized basis depending on other clinical and patho-
logic features of the primary tumor.
T-stage, tumor grade, and margin status were also found to be
associated OS and DFS in the univariate analysis, with margin status
not surprisingly retaining significance on multivariate analysis (Table 3,
Figure 2A,B). Due to incomplete reporting, tumor grade was removed
F IGURE 1 Kaplan-Meier curves of A, overall survival and B,
disease-free survival by histologic type show a highly significant
impact of histology on survival
TABLE 3 Multivariate Cox
proportional hazards model for predictors
of OS and DFS
Predictor HR (OS) [95% CI] P value HR (DFS) [95% CI] P value
Age > 60 2.17 [0.99-5.27] .05 1.81 [0.93-3.76] .08
Histology “Other” 3.23 [1.54-6.81] .002 3.08 [1.59-5.99] .001
Positive margin 2.05 [1.01-4.25] <.05 2.29 [1.21-4.38] .01
T stage (1/2 vs 3/4) 1.52 [0.66-3.67] .33 1.83 [0.87-4.02] .11
N stage (N0 vs N+) 2.05 [1.02-4.06] .04 1.98 [1.06-3.68] .03
FN involvement 2.62 [1.17-5.80] .02 2.32 [1.15-4.66] .02
Note: Although it was significant in the univariate model, grade was eliminated from the multivariate
model due to incomplete reporting.
Abbreviations: CI, confidence interval; DFS, disease-free survival; FN, facial nerve; HR, hazard ratio; OS,
overall survival.
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from the multivariate analysis, though we anticipate that it remains a
significant factor in determining prognosis. In mucoepidermoid and
acinic cell carcinomas, for example, prior studies have shown 5-year
OS to be as high as 100% in low-grade tumors, decreasing to 50% for
higher grade tumors.25,26 At minimum, we conclude that more uni-
form reporting and additional study of the prognostic impact of tumor
grade in salivary gland malignancies is warranted. T-stage lost signifi-
cance in the multivariate analysis, and we hypothesize that this finding
suggests that other clinicopathologic measures better captured the
biologic impact of larger tumors.
Limitations of our study include its retrospective nature, reliance
on the documentation in the electronic medical record, and approxi-
mation of survival by last known communication with the patient. We
recognize that this approach to determining survival may underesti-
mate true survival, given lack of follow-up, or transfer of care from a
tertiary referral center to alternate providers with no documented
communication. We also acknowledge that it may be biased by pro-
vider determined need for follow-up and may particularly affect strati-
fication by histology. However, our results of survival, both overall
and stratified by histology, are consistent with prior reports in the
F IGURE 2 Kaplan-Meier curves of overall survival and disease-free survival by A and B, margin status, C and D, N stage, and E and F, facial
nerve involvement show highly significant impacts of each of these variables on survival
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literature, thus supporting the validity of our data. The diverse group
of histopathologic subtypes makes it challenging to comment upon
how the specific histologic subtype may affect long-term outcomes,
particularly for less common malignancies. Moreover, we recognize
that classification of parotid malignancies has evolved in the past
decade, leading to potential underreporting of secretory carcinomas
and insufficient classification of carcinoma ex pleomorphic adenomas.
In addition, incomplete reporting limited our comment on the impact
of tumor grade and highlight the importance of histopathologic
assessment of this metric, as it is likely that grade does have an impact
on outcomes. However, we hope that our relatively large, single insti-
tution cohort of parotid malignancies can contribute to an under-
standing of the relative demographics and differences in prognosis of
the variety of salivary gland malignancies commonly treated by the
head and neck surgeon.
5 | CONCLUSIONS
We report outcomes on 200 consecutive patients with malignancies
of the parotid gland managed surgically at a single institution. In our
cohort, we found that histologic subtype, N-stage, and FN involve-
ment were independent predictors of both OS and DFS. Tumors such
as salivary ductal carcinoma were associated with early recurrence,
whereas adenoid cystic carcinoma was associated with late
recurrence.
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ENDNOTE
*HR > 100 in this case represents the infinite solution resulting from the
fact that there were no events in the low-grade group, thus making this a
highly significant effect.
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